This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket
by Zacks Equity Research
Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in attractive, higher-growth segments.
ALGN Q4 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Align Technology reports fourth-quarter 2024 revenue growth. This can be mostly attributed to the robust performance of the Imaging Systems & CAD/CAM Services business segment.
STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket
by Zacks Equity Research
STERIS' third-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The lowered revenue guidance for fiscal 2025 is concerning.
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
by Zacks Equity Research
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Investors Hold Chemed Stock in Their Portfolio Now?
by Zacks Equity Research
CHE stays on investors' radar due to its robust prospects in the VITAS business and the resilient Roto-Rooter arm.
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IDEXX Q4 Earnings and Revenues Top Estimates, Stock Up in Pre-Market
by Zacks Equity Research
IDXX delivers better-than-expected earnings and revenues in the fourth quarter of 2024.
Quest Diagnostics (DGX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
DGX Stock Dips Despite Q4 Earnings and Revenue Beat, Margins Rise
by Zacks Equity Research
Quest Diagnostics' fourth-quarter 2024 performance benefits from the strength of its core business.
Quest Diagnostics (DGX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.83% and 1.96%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
Quest Diagnostics is likely to have driven strong performances in the key physician and hospital channels in the fourth quarter of 2024.
Zacks Industry Outlook Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.
4 Stocks to Monitor in a Dynamic Outpatient Home Health Industry
by Debanjana Dey
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, OPCH and ADUS are well-poised to gain.
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus
by Santanu Roy
Our time-tested methodologies helped investors navigate the market well last week. Here are some of our key performance data from the past three months.
Why Quest Diagnostics (DGX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Hold Quest Diagnostics Stock in Your Portfolio Now?
by Zacks Equity Research
DGX's strength in the base business and the robust adoption of Advanced Diagnostics services bode well.
New Health Coaching Service on questhealth.com Set to Boost DGX Stock
by Zacks Equity Research
Quest Diagnostics introduces Health Coaching on questhealth.com, helping individuals take control of their health.
Why Is Encompass Health (EHC) Up 3.8% Since Last Earnings Report?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics (DGX) Up 2.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SYK Stock Rises Following the Launch of Next Generation SurgiCount+
by Zacks Equity Research
Stryker launches the next generation of SurgiCount+ to boost sponge management and blood loss assessment in hospitals.
GEHC Stock Falls Despite FDA Clearance for SIGNA MAGNUS MRI System
by Zacks Equity Research
GE Healthcare receives FDA clearance for its head-only SIGNA MAGNUS 3.0T MRI System.
All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy
by Zacks Equity Research
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cardinal Health Stock Gains Following Two Strategic Acquisitions
by Zacks Equity Research
CAH announces two strategic acquisitions to strengthen its multi-specialty and at-Home Solutions businesses.